Rhythm Pharmaceuticals presented data at the Endocrine Society’s Annual Meeting showing significant reductions in BMI for patients with acquired hypothalamic obesity. Results from Phase 2 trial of bivamelagon demonstrated up to 9.3% BMI reduction. Phase 3 trial of setmelanotide showed a 19.8% placebo-adjusted BMI reduction and significant reductions in participants with prior or concomitant use of GLP-1s. A qualitative interview sub-study also provided insights from patients or caregivers. These findings highlight the potential of MC4R targeted therapies, like setmelanotide, to become standard care for patients with acquired hypothalamic obesity.

Read more at GlobeNewswire: Rhythm Pharmaceuticals Presents Data on MC4R Agonists